Real World Practice Indirect Comparison Between Guselkumab and Risankizumab: Results from an Italian Retrospective Study

Overview

Journal Dermatol Ther

Specialty Dermatology

Date 2021 Nov 20

PMID 34800070

Citations 20

Authors

Angelo Ruggiero

Gabriella Fabbrocini

Eleonora Cinelli

Matteo Megna

Affiliations

Soon will be listed here.

Abstract

IL-23-inhibitors, such as guselkumab and risankizumab, represent the newest class of biologics approved for psoriasis. Phase III trials have shown their efficacy and safety. However, real life data are still scant. to indirectly compare the effectiveness, safety and tolerability of guselkumab and risankizumab in real world practice. An Italian single-center retrospective cohort study enrolling moderate-to-severe psoriasis patients from September 1, 2018 and December 31, 2020 was performed to indirectly compare guselkumab and risankizumab efficacy and safety. Sixty eight patients were included (36 received guselkumab and 32 risankizumab). The groups were comparable for all analyzed characteristics, except for mean psoriasis duration (p < 0.01) which was higher for guselkumab. In guselkumab group, mean PASI reduced from 16.1 ± 6.4 (baseline) 2.1 ± 0.9 (week-28) (p < 0.001) up to 0.9 ± 0.8 (week-44) (p < 0.001). In risankizumab group mean PASI decreased from 13.5 ± 4.9 (baseline) 1.9 ± 0.8 (p < 0.001), (week-28) (p < 0.001) up to 0.9 ± 0.4 (week-40) (p < 0.001). No significant difference in mean PASI and BSA were observed between the treatments. No cases of serious AEs, injection site reaction, candida, malignancy, cardiovascular events were reported in both groups. Guselkumab and risankizumab showed favorable efficacy and safety profile, being comparable in terms of PASI90 and PASI100 responses as well as in AEs frequency and discontinuation rates.

Citing Articles

Real Life Comparative Effectiveness of IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Multicenter Experience.

Borghi A, Odorici G, Bardazzi F, Filippi F, Bigi L, Lasagni C Dermatol Pract Concept. 2024; 14(3).

PMID: 39122527 PMC: 11314075. DOI: 10.5826/dpc.1403a179.

Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data.

Ding L, Chen C, Yang Y, Zhang X Front Immunol. 2024; 15:1349636.

PMID: 38384460 PMC: 10879569. DOI: 10.3389/fimmu.2024.1349636.

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics.

Ruggiero A, Portarapillo A, Megna M, Patruno C, Napolitano M Pediatric Health Med Ther. 2023; 14:435-451.

PMID: 38024562 PMC: 10656860. DOI: 10.2147/PHMT.S389108.

Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: a prospective study.

Timis T, Beni L, Florian I, Orasan M, Orasan R Med Pharm Rep. 2023; 96(4):368-383.

PMID: 37970199 PMC: 10642736. DOI: 10.15386/mpr-2631.

The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.

Qiu J, Liu J, Liu W, Lin F, Shi N Front Med (Lausanne). 2023; 10:1264667.

PMID: 37841017 PMC: 10570425. DOI: 10.3389/fmed.2023.1264667.

References

Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke W . The role of IL-23 and the IL-23/T 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017; 31(10):1616-1626. PMC: 5697699. DOI: 10.1111/jdv.14433. View

Reich K, Armstrong A, Langley R, Flavin S, Randazzo B, Li S . Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019; 394(10201):831-839. DOI: 10.1016/S0140-6736(19)31773-8. View

Megna M, Balato A, Napolitano M, Gallo L, Caso F, Costa L . Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules". Clin Rheumatol. 2018; 37(7):1739-1741. DOI: 10.1007/s10067-018-4090-6. View

Di Cesare A, Di Meglio P, Nestle F . The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009; 129(6):1339-50. DOI: 10.1038/jid.2009.59. View

Megna M, Balato A, Raimondo A, Balato N . Guselkumab for the treatment of psoriasis. Expert Opin Biol Ther. 2018; 18(4):459-468. DOI: 10.1080/14712598.2018.1445223. View

Galluzzo M, Tofani L, Lombardo P, Petruzzellis A, Silvaggio D, Egan C . Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study. J Clin Med. 2020; 9(7). PMC: 7408922. DOI: 10.3390/jcm9072170. View

Blauvelt A, Papp K, Griffiths C, Randazzo B, Wasfi Y, Shen Y . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active.... J Am Acad Dermatol. 2017; 76(3):405-417. DOI: 10.1016/j.jaad.2016.11.041. View

Al-Salama Z, Scott L . Guselkumab: A Review in Moderate to Severe Plaque Psoriasis. Am J Clin Dermatol. 2018; 19(6):907-918. DOI: 10.1007/s40257-018-0406-1. View

Maliyar K, OToole A, Gooderham M . Long-Term Single Center Experience in Treating Plaque Psoriasis With Guselkumab. J Cutan Med Surg. 2020; 24(6):588-595. DOI: 10.1177/1203475420932514. View

10.

Macaluso F, Orlando A, Cottone M . Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. Expert Opin Biol Ther. 2018; 19(2):89-98. DOI: 10.1080/14712598.2019.1561850. View

11.

Ruggiero A, Fabbrocini G, Cinelli E, Megna M . Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti-interleukin-17 treatment: A real-life 52-week retrospective study. Dermatol Ther. 2020; 34(1):e14673. DOI: 10.1111/dth.14673. View

12.

Gottlieb A, Saure D, Wilhelm S, Dossenbach M, Schuster C, Smith S . Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12. J Dermatolog Treat. 2020; 33(1):54-61. DOI: 10.1080/09546634.2020.1747592. View

13.

Warren R, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T . Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2020; 184(1):50-59. PMC: 7983954. DOI: 10.1111/bjd.19341. View

14.

Gisondi P, Piaserico S, Naldi L, Dapavo P, Conti A, Malagoli P . Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. J Allergy Clin Immunol. 2020; 147(2):558-560.e1. PMC: 7644231. DOI: 10.1016/j.jaci.2020.10.032. View

15.

Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L . Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020; 33(6):e13964. DOI: 10.1111/dth.13964. View

16.

Fougerousse A, Ghislain P, Reguiai Z, Maccari F, Parier J, Bouilly Auvray D . Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. J Eur Acad Dermatol Venereol. 2020; 34(10):e644-e646. DOI: 10.1111/jdv.16511. View

17.

Hawkes J, Yan B, Chan T, Krueger J . Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J Immunol. 2018; 201(6):1605-1613. PMC: 6129988. DOI: 10.4049/jimmunol.1800013. View

18.

Megna M, Ruggiero A, Marasca C, Fabbrocini G . Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatolog Treat. 2020; 31(4):328-329. DOI: 10.1080/09546634.2020.1757605. View

19.

Benhadou F, Ghislain P, Guiot F, Willaert F, Del Marmol V, Lambert J . Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020; 34(12):e837-e839. DOI: 10.1111/jdv.16715. View

20.

Gordon K, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y . Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018; 392(10148):650-661. DOI: 10.1016/S0140-6736(18)31713-6. View